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SUMMARY 
Castleman’s disease is a rare cause of lymphoid 
hyperplasia that may result in localized symptoms or 
an aggressive, multisystem disorder that can mimic 
other diseases like lymphoma or tuberculosis. We 
describe a case of a 55-year-old Ghanaian male who 
was successfully diagnosed and managed for 
multicentric Castleman’s disease with combination 
chemotherapy.  
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INTRODUCTION 
Castleman’s disease, first described in 1954, is a rare 
disorder characterized by hyperplasia of lymphoid 
tissue.1 Histopathologically, three sub-types are 
recognized: hyaline vascular (HV) variant, plasma cell 
(PC) variant and the mixed variant.2  
 
Clinical presentation is varied, ranging from unicentric 
or localized lymph node involvement to a severe, 
multicentric, systemic disorder associated with 
constitutional signs and symptoms such as fever, night 
sweats, easy fatigability and anaemia.3,4 With localized 
disease, surgical resection of the affected lymph node 
is usually curative. However, multicentric Castleman’s 
disease (MCD) often requires aggressive systemic 
therapy.2,4   
 
We present a patient with MCD who is in remission 
following treatment with multiagent chemotherapy and 
Rituximab (anti-CD-20 monoclonal antibody). To the 
best of our knowledge, this is the first report of 
Castleman’s disease with marked systemic symptoms 
in Ghana. 
 
CASE REPORT  
A 55-year-old Ghanaian male was referred to the 
Haematology clinic at Korle Bu Teaching Hospital, 
Accra for investigation of a suspected lymphoma. He 
presented with a 9 month history of fever, weight loss 
and productive cough (no haemoptysis). 
 
On examination, he was pale and had palpable, firm, 
non-tender, right axillary lymph nodes; the largest 
measuring 2 x 2 cm.  Abdominal examination 
demonstrated an enlarged liver (7cm below the right 
costal margin) and a palpable splenic tip. Respiratory 
and cardiovascular systems were normal.  
 
Laboratory examination revealed normocytic, 
normochromic anaemia (haemoglobin 9.6g/dl) but 
otherwise normal blood counts (Table 1). Erythrocyte 
sedimentation rate was elevated (51mm/hr). Liver 
enzymes, serum creatinine and lactate dehydrogenase 
levels were normal. A bone marrow aspirate revealed 
elevated marrow lymphocytes comprising 30% of 
nucleated cells, which appeared non-malignant 
morphologically. Mantoux test, HIV, Hepatitis B and C 
viral screening were negative. Human herpes virus 8 
(HHV8) testing was negative. 
 
Table 1 Summary of full blood count and ESR results 





Hb (g/dl) 8.9 13.4g/dl 13.5- 18.0 
MCV (fl ) 81 85.0fl 80.0-96.0 
MCH (pg) 29.1 28.8pg 26.0 - 32.0 
WBC (x 109/L) 3.6 4.1 x 109/L 4.0 - 11.0 
Platelets  (x 109/L)  141 196 X 109/L 150 - 400 
Reticulocyte count 
(%)  0.4  0.5-2.5 
ESR (mm/hr)  51  0- 14 
ESR = erythrocyte sedimentation rate 
 
Computed tomography (CT) scan of the chest and 
abdomen were done to assess extent of disease and 
revealed cardiomegaly, mild bilateral pleural effusions, 
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Table 2 Summary of immunohistochemistry of lymph 
node biopsy 
MARKERS  FINDINGS 
CD13 Stained scattered plasma cells 
Kappa Stained scattered plasma cells. 
No light chain clonality demon-
strated 
Lambda Stained scattered plasma cells. 
No light chain clonality demon-
strated 
CD3 Stained scattered T-cells in the 
interfollicular zones 
CD20 Stained B-cells in the germinal 
centers and mantle zones. 
Bcl-6 Stained few lymphoid cells 
CD23 Stained germinal centers. 
Bcl -2 Stained B-cells in the germinal 
centers and mantle zones 
Bcl -1 (Cyclin D1): Stained no lym-
phoid cells 
CD21 Stained germinal centers 
IgD Stained no lymphoid cells 
 
The immunohistochemistry report was similar to 
reactive lymphoid hyperplasia showing normal CD 20, 
23, 21 and Bcl-2 staining of germinal centers. Staining 
of CD 138 demonstrated the presence of plasma cells 
and staining of both kappa and lambda light chains 
showed that the disease is polyclonal.  
 
An axillary lymph node biopsy was performed and 
histology showed partially effaced architecture with 
follicles of varying sizes, expansion of the paracortex 
and concentric arrangement of lymphocytes around 
venules and plasma cells in the inter-follicular spaces. 
There was no evidence of a malignant lymphoma. 
 
A diagnosis of Castleman’s disease (PC variant) was 
made based on the histopathologic findings in Figures 
1 and 2 and  immunohistochemical test results (Table 
2). The patient was started on combination 
chemotherapy comprising cyclophosphamide, 
vincristine, prednisolone, as well as rituximab, given at 
three weekly intervals. In total, he received six cycles 
of therapy.  
 
With the commencement of chemotherapy, there was 
rapid improvement in his clinical symptoms and 
resolution of peripheral lymphadenopathy and hepato-
splenomegaly.  
 
A repeat chest x-ray after 6 cycles showed normal 
cardiac size and lung fields. Repeat blood counts were 
normal. Liver and renal function also remained normal. 
The patient is very well 12 months off therapy. 
 
 
Figure 1 Section showing a reactive lymph node with 
few plasma cells in the interfollicular zone (Magnifica-
tion x 100) 
  
 
Figure 2 Section of lymph node showing partially ef-
faced architecture with follicles of varying size scat-
tered throughout the node. (Magnification x 4) 
 
DISCUSSION  
The aetiology of Castleman’s remains unclear although 
viral agents such as HHV-8 and HIV have been 
associated with the disease.5,6 MCD has also been 
described in association with Kaposi sarcoma, 
autoimmune disorders and the POEMS (Peripheral 
polyneuropathy, Organomegaly, Endocrinopathy, 
Monoclonal gammopathy (M-Protein) and Skin signs) 
syndrome.2,6-8  
 
Castleman’s disease can be found throughout the body 
at both nodal and extranodal sites. The mediastinum 
and neck remain the most common sites for unicentric 
disease.9 While Castleman’s disease can occur at any 
age, most cases of localized disease occur in 
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However, MCD commonly presents at an older age, 
usually in the fourth or fifth decade, as was the case in 
our patient.3,10 No significant sex predilection has been 
found, regardless of the histologic type.2,9  
 
The clinical manifestations of Castleman’s disease are 
highly dependent on the histopathology of the lesion. 
The HV variant is usually associated with unicentric 
Castleman’s disease while PC and mixed variants 
occur more commonly in MCD.2,11    
 
Patients with MCD present with non-specific 
symptoms such as fever, weight loss and night sweats 
that may mimic malignant lymphoma, tuberculosis or 
HIV/AIDS. They may also present with organ failure.3 
Recent studies show that such systemic manifestations 
may be due to intra-lesional cytokine dysregulation 
involving interleukin 1 (IL-1), tumor necrosis factor 
alpha (TNF-a), and interleukin 6 (IL-6).12 Beck et al13 
showed that the generation of IL-6 in the germinal 
centers of hyperplastic lymph nodes and subsequent 
complex interactions with IL-1 and TNF-a may be the 
key elements responsible for the systemic 
manifestations of Castleman’s disease. 
 
Other clinical signs include peripheral 
lymphadenopathy and hepatosplenomegaly which were 
present in our patient. Features of POEMS syndrome 
may be present. Isolated case reports also recount such 
atypical features as peripheral neuropathy, myasthenia 
gravis, recurrent pleural effusion, amyloidosis, growth 
retardation, and nephrotic syndrome. 14,15 
 
Laboratory features are also non-specific and include 
high erythrocyte sedimentation rate (ESR), anaemia 
and hypoalbuminaemia. Anaemia may be due to the 
chronic nature of the disease. Lymph node biopsies and 
histological evaluation are essential for diagnosis of 
Castleman’s disease and help exclude malignancy as 
well as other causes of hyperplasia.6 
  
While unicentric Castleman’s disease can be cured by 
surgical excision of the affected lymph nodes (or local 
radiotherapy for unresectable sites)4, MCD usually 
requires systemic therapy. Treatment options include 
corticosteroids, antiviral agents, anti-CD20 antibodies 
(Rituximab), anti-interleukin-6 receptor antibodies and 
chemotherapy5, Splenectomy may also result in 
improvement of symptoms.17  
 
The use of highly active antiretroviral therapy 
(HAART) alone in HIV-associated MCD has resulted 
in complete remission in some patients.18 Prompt 
therapy must be instituted to avoid potentially fatal 
complications from organ failure and infections. 
Complete response has been defined as the complete 
disappearance of all measureable and evaluable 
disease.6 Relapses may occur and high dose 
chemotherapy and autologous stem cell transplantation 
has been used with success.2,19 There are no 
randomized clinical trials evaluating any of these 
treatment strategies.  
 
CONCLUSION 
MCD should be considered in the differential 
diagnoses of patients presenting with peripheral 
lymphadenopathy and non-specific systemic 
symptoms. Early diagnosis is imperative given its 
progressive clinical course and increased risk for 
development of lymphoma. Empiric treatment options 
include steroids, chemotherapy and newer biologically 
targeted therapies like monoclonal antibodies.  
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